Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurocrine BiosciencesSTU:NB3 -1.23%93 PB Ratio is 5.23 as of Jul. 14, 2026, which is 30% below its 10-year median of 7.42. GuruFocus rates STU:NB3 with a GF Score™ of 93/100 and a GF Value™ of €166.59 (Fairly Valued). The stock has 6 warning signs investors should review. Among 921 Drug Manufacturers companies, Neurocrine Biosciences ranks worse than 82.63% on this metric.
Neurocrine Biosciences Inc stock PB Ratio (=5.14) is close to 1-year high of 5.33.
The historical rank and industry rank for Neurocrine Biosciences's PB Ratio or its related term are showing as below:
STU:NB3'
s PB Ratio Range Over the Past 10 Years
Min: 3.55 Med: 7.42 Max: 29.45
Current: 5.14
During the past 13 years, Neurocrine Biosciences's highest PB Ratio was 29.45. The lowest was 3.55. And the median was 7.42.
STU:NB3's PB Ratio is ranked worse than 82.63% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs STU:NB3: 5.14
During the past 12 months, Neurocrine Biosciences's average Book Value Per Share Growth Rate was 32.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 22.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 22.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 26.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Neurocrine Biosciences was 195.50% per year. The lowest was -77.90% per year. And the median was 19.80% per year.
Back to Basics: PB Ratio
Neurocrine Biosciences (STU:NB3) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Neurocrine Biosciences (STU:NB3) has a PB Ratio of 5.23 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Neurocrine Biosciences and its competitors. This is 30% below median its historical median of 7.42. Over the past decade, Neurocrine Biosciences' PB Ratio has ranged from 3.55 to 29.45. According to the industry distribution chart, Neurocrine Biosciences ranks #761 out of 921 companies in the Drug Manufacturers industry, placing it in the top 82.6%.
Is Neurocrine Biosciences' PB Ratio too high?
Neurocrine Biosciences' current PB Ratio of 5.23 is 30% below median its 10-year median of 7.42. Over the past 10 years, this metric has ranged from a low of 3.55 to a high of 29.45. The Drug Manufacturers industry median PB Ratio is 1.90. Neurocrine Biosciences' value of 5.23 is 175.3% above this industry median. Based on the distribution chart, Neurocrine Biosciences ranks #761 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Neurocrine Biosciences has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' PB Ratio compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #761 out of 921 companies for PB Ratio. This places Neurocrine Biosciences in the lower half of its industry. The industry median PB Ratio is 1.90. Neurocrine Biosciences' value of 5.23 is 175.3% above this benchmark. Historically, Neurocrine Biosciences' own PB Ratio has ranged from 3.55 to 29.45 over the past decade. While the company's 10-year median is 7.42 vs. the industry median of 1.90, Neurocrine Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current PB Ratio of 5.23 is 175.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current PB Ratio is 5.23, which is 30% below median its own 10-year median of 7.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (STU:NB3) is currently considered Fairly Valued. The stock's GF Value™ is €166.59, compared to a current price of €153.15 — trading 8.1% below its estimated fair value. The current PB Ratio is 5.23, which is 30% below median its 10-year median of 7.42 and 175.3% above the Drug Manufacturers industry median of 1.90. Neurocrine Biosciences' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Neurocrine Biosciences (STU:NB3), the current PB Ratio is 5.23 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (STU:NB3) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of €153.15 is trading 8.1% below its estimated GF Value™ of €166.59.
GuruFocus considers Neurocrine Biosciences to be Fairly Valued.
Key valuation signals for STU:NB3:
PB Ratio: 5.23 (30% below median its 10-year median of 7.42)
GF Value™: €166.59 vs. price of €153.15 (8.1% below fair value)
Industry Position: 175.3% above the Drug Manufacturers median (#761 of 921)
No single metric tells the full story. See the STU:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
93GF Score
Get the complete analysis for STU:NB3
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:NB3 has been successfully added to your 
